Medtronic PLC Stock (MDT) Moved Up by 5.59% on Jun 3: Facts Behind the Movement

Medtronic PLC (MDT) moved up by 5.59%. The Healthcare Services & Equipment sector is up by 0.63%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) up 0.95%; Medtronic PLC (MDT) up 5.59%; Intuitive Surgical Inc (ISRG) up 0.88%.

What is driving Medtronic PLC (MDT)’s stock price up today?

Medtronic's shares experienced an increase today, largely driven by a combination of strong financial results and strategic corporate developments.

The company reported its fourth quarter and full fiscal year 2026 earnings, which included revenue figures that surpassed analyst expectations. Revenue for the fourth quarter demonstrated robust growth, with both reported and organic figures exceeding implied guidance. Furthermore, Medtronic delivered its highest annual revenue growth in ten years for fiscal year 2026. The company also issued an optimistic outlook for fiscal year 2027, projecting solid organic revenue growth and diluted non-GAAP earnings per share. Complementing these financial highlights, Medtronic announced an increase in its quarterly dividend for the first quarter of fiscal year 2027. These positive financial data points, particularly the strong revenue performance and favorable future guidance, contributed significantly to investor confidence.

In addition to the earnings report, Medtronic announced several key strategic initiatives. The company submitted 510(k) filings to the U.S. Food and Drug Administration (FDA) to broaden the indications for its Hugo robotic-assisted surgery (RAS) system to include general and gynecologic procedures. This expansion aims to enhance the system's market reach and capabilities. Medtronic also secured 510(k) clearance for its ProGrip Advanced mesh, intended for use in robotic-assisted ventral hernia repair.

Further reinforcing its market position, Medtronic disclosed strategic investments in two private companies focused on advancing intracardiac echocardiography (ICE) catheter technologies. These investments are designed to integrate ICE capabilities into Medtronic's Affera mapping and ablation system, thereby strengthening its cardiac ablation business. The company also has plans to acquire SPR Therapeutics for approximately $650 million, which will add FDA-cleared temporary peripheral nerve stimulation technology, expanding Medtronic's portfolio for chronic pain management. While some analyst price targets were adjusted, the overall sentiment regarding these strategic moves and the company's financial performance appears to be overwhelmingly positive.

Technical Analysis of Medtronic PLC (MDT)

Technically, Medtronic PLC (MDT) shows a MACD (12,26,9) value of [-1.98], indicating a sell signal. The RSI at 31.15 suggests neutral condition and the Williams %R at -92.59 suggests oversold condition. Please monitor closely.

Media Coverage of Medtronic PLC (MDT)

In terms of media coverage, Medtronic PLC (MDT) shows a coverage score of 48, indicating a moderate level of media attention. The overall market sentiment index is currently in bearish zone.

Fundamental Analysis of Medtronic PLC (MDT)

Medtronic PLC (MDT) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $33.54B, ranking 4 in the industry. The net profit is $4.66B, ranking 3 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $0.00, a high of $0.00, and a low of $0.00.

More details about Medtronic PLC (MDT)

Company Specific Risks:

• Medtronic initiated a Class II FDA recall in April 2026 for its SynchroMed Flex Infusion Mode clinician programmer software due to a scheduling bug, affecting over 10,000 units globally and highlighting ongoing execution risks related to the integration of complex digital components in implanted medical devices.
• Multiple institutional analysts have recently lowered their price targets for MDT, including Mizuho (from $120 to $100 on June 3, 2026) and Needham (from $120 to $101 on June 3, 2026), indicating a more conservative valuation outlook and potential reassessment of near-term growth prospects.
• The company reported a 230 basis point decline in its adjusted operating margin in Q4 FY26, impacted by the MiniMed Blackstone payment and tariffs, signaling persistent operational headwinds that could pressure future profitability.
• Recent insider activity reports show significant share sales by executives, including Harry Skip Kiil (EVP & President Cardiovascular) selling over $5 million worth of shares in the past six months, which could be interpreted as a potential lack of strong confidence in the company's short-term trajectory by management.